The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Pharmaceutical and Life Sciences Real World Evidence: Market Landscape and Competitive Insights, 2018-2030

  • Lowest Price Guaranteed From USD 3,499

  • Published
    October 2018

  • Pages
    264

  • View Count
    5392

Example Insights

 

 

Overview

In recent years, the healthcare industry has witnessed a number of efforts by stakeholders to utilize real world evidence-based insights in official decision making processes; several regulatory authorities / payers have also started acknowledging the potential of real world data and have begun considering insights generated from such data sources for various purposes.

-Head of Market Strategy, a UK-based small-sized real world data provider

The process of developing new and disruptive medical products involves heavy investments, both in terms of time and cost. Estimates suggest that each prescription drug requires an average of about 10 years and over USD 2.5 billion in working capital before it gets commercialized. In order to gain regulatory approval and establish standards for the safety and efficacy of these products, randomized clinical trials (RCTs) are conducted; these account for a staggering 40% of the pharmaceutical industry’s budget.In addition to excessive R&D costs, these trials are fraught with various other challenges, such as prolonged delays and risk of failure / termination. It is also worth highlighting that most clinical trials are conducted under controlled conditions and involve a fairly homogenous patient population; however, when such products are approved, there are a variety of factors (both genetic and environmental) that need to be considered while treating individual patients. Data generated from real world applications of drug / therapy products partly addresses the aforementioned complexities and serves to complement the insights derived from controlled RCTs.

Real world evidence has demonstrated the potential to validate the therapeutic value of pharmaceutical products and help customize product development in a more patient centric manner. In December 2016, the 21st Century Cures Act was passed directing the FDA to evaluate the applications of real world evidence in supporting healthcare decision-making. Its numerous applications have further encouraged pharmaceutical companies and health economists to utilize it in the evaluation of product candidates targeting even the rarest of medical conditions. In fact, it is estimated that, on an average, a big pharmaceutical company spends nearly USD 20 million annually for generating real world evidence-based insights. The growing importance of real world evidence in healthcare decision-making is also evident from the number of tweets (~4,400) posted on the social media platform, Twitter, in recent years. It is also worth noting that, since 2017, close to 75 global events (which include summits, forums, conferences and annual meetings) have been organized to discuss different aspects of real world evidence. Further, in the past few years, more than 1,000 studies have been initiated by stakeholders in real world setting to assess the impact of pharmacologic / non-pharmacologic treatment on patients and healthcare systems. Various initiatives are underway to further explore the potential of real world evidence in different stages of drug development. We believe that such efforts are likely to boost the overall growth of this market in the coming years.

 

Scope of the Report

The ‘Pharmaceutical and Life Sciences Real World Evidence: Market Landscape and Competitive Insights, 2018-2030’ report features an extensive study on the industry players that are offering real world data / analytics / services to the pharmaceutical and life sciences industries. Amongst other elements, the report features:

  • An overview of the current status of the market with respect to the companies providing real world evidence related solutions. It features information on their year of establishment, geographical location, size of the company, type of offering (real world data, analytics, and services), real world data sources (medical claims, clinical trials, clinical setting, pharmacy, patient-powered and others), and intended application areas (early stage research, clinical development, regulatory submission / reimbursement / market access, and post-approval studies).
  • An elaborate discussion on data governance and the existing regulatory framework related to real world evidence across various geographies, namely North America (the US and Canada), Europe (the UK, Germany, France, Spain and Italy), and Asia-Pacific (Australia, China and Japan).
  • A detailed publication analysis of close to 500 articles that have been published since 2016, highlighting the key focus areas of ongoing real world evidence-based research activity in the pharmaceutical and life sciences industries. The analysis also highlights the key prevalent trends associated with these publications, including information on the types of real world data sources utilized, leading indications, active stakeholders, and the most popular journals within this domain.
  • A comprehensive analysis of completed, ongoing and planned studies conducted in the real world setting. For the purpose of this analysis, we considered only those studies that have been last updated since 2013, and analyzed them on the basis of various parameters, such as current trial status, regional distribution, type of sponsor, target indications, and enrolled patient population across different geographies.
  • An analysis depicting the prevalent and emerging trends related to this domain as represented on the social media platform, Twitter. In addition to providing information on yearly trends related to the volume of tweets since 2013, the analysis highlights the most frequently talked about real world data sources, applications, therapeutic areas, active players, and influential authors.
  • An in-depth analysis of recent events (summits / forums / conferences / annual meetings) that were organized for stakeholders in this domain, highlighting the evolution of discussion topics related to real world evidence. The analysis also provides details on event type, regional distribution, emerging agendas, popular organizers, active industry and non-industry players, and a schematic mapping of upcoming planned events.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall real world evidence market.
  • A comparative analysis of the needs of different stakeholders (manufacturers, regulators, payers, providers and patients) involved in this domain.
  • A list of recent use cases where real world evidence was leveraged by pharmaceutical / medical device companies, highlighting the ways in which companies have utilized such information to support regulatory decisions, advance disease understanding, and develop outcome-based reimbursement model.
  • An insightful opportunity analysis, estimating the existing market size and potential growth opportunities across different applications (early stage research, clinical development, regulatory approval, pricing / reimbursement, and post-approval studies) of real world evidence. Based on multiple parameters, such as number of pre- or post-approval studies conducted annually, investment associated with these studies, and the likely cost and time saving opportunities, we have provided an informed estimate on the likely evolution of the market over the period 2018-2030.

The opinions presented in this study were influenced by inputs (through a comprehensive survey) of several key players in this domain. In addition, the report features detailed transcripts of interviews held with the following individuals:

  • Jane Reed (Head of Life Science Strategy, Linguamatics)
  • Jonathan Moshinsky (Head of Market Strategy, uMotif)
  • Anonymous (Vice President, Big Pharmaceutical Company)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the real world evidence market in the mid to long term.

Chapter 3 is an introductory chapter that presents a general overview of investment required for developing new medical products, along with information on the limitations associated with RCTs. Further, it features a detailed discussion on the growing importance of real world evidence and its potential to complement RCTs in healthcare decision-making. It also features a description of the process of generating real world evidence from the raw, unstructured data, along with details on different sources of data, and the potential applications of real world evidence. Further, the chapter features a discussion on the key growth drivers and roadblocks related to real world evidence, and the novel technologies that are likely to have a notable impact on the industry’s evolution over the coming decade.

Chapter 4 provides a detailed description on the primary elements of data governance and regulatory framework related to real world evidence across various geographies, namely North America (the US and Canada), Europe (the UK, Germany, France, Spain and Italy), and Asia-Pacific (Australia, China and Japan).

Chapter 5 provides a comprehensive overview of the industry players that are actively involved in providing real world evidence solutions. The chapter presents analysis of these players on the basis of their year of establishment, geographical location, size of the company, type of offering (real world data, analytics, and services), real world data sources used (medical claims, clinical trials, clinical setting, pharmacy, patient-powered and others), and intended application areas (early stage research, clinical development, regulatory submission / reimbursement / market access, and post-approval studies).

Chapter 6 provides a detailed analysis of close to 500 research articles related to real world evidence that have been published since 2016. The analysis takes into consideration several parameters, such as the year of publication, key focus areas, types of real world datasets utilized, indications, active stakeholders, geographical distribution of the authors and the journals. The chapter also highlights the various attempts that are being made to add value to the ongoing R&D efforts within this domain.

Chapter 7 provides a comprehensive clinical trial analysis of completed, ongoing and planned studies, assessing the real world impact of pharmacologic / non-pharmacologic treatment on patients. For the purpose of this analysis, we looked at the clinical studies that have been last updated since 2013, and analyzed them on the basis of various parameters, such as current trial status, trial registration year, geographical distribution and enrolled patient population across different geographies, type of study, leading industry and non-industry players, grid mapping of key therapeutic areas, and trial benchmarking for leading industry players.

Chapter 8 provides insights on the popularity of real world evidence on the social media platform, Twitter. The chapter highlights the yearly distribution of tweets posted on the platform in the period between January 2013 and June 2018, and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter showcases the most frequently mentioned keywords, real world data sources, applications, therapeutic areas and players, on the social media platform. It elucidates the most prolific authors and presents a bubble analysis of the most influential authors related to real world evidence on Twitter.

Chapter 9 features insights obtained from an in-depth analysis of the global real world evidence events organized for stakeholders in this domain. For the purpose of this analysis, we looked at the summits, forums, conferences, and annual meetings that have been organized since 2017 and analyzed these events on the basis of various parameters, such as event type, location, event agendas, organizers, and industry and non-industry participants. The chapter also highlights the evolution of discussion topics related to real world evidence.

Chapter 10 provides details on the key parameters and trends that are likely to influence the future of the real world evidence market, under a comprehensive SWOT framework. The chapter also features a schematic Harvey ball analysis to highlight the relative impact of each SWOT parameter on the overall real world evidence market.

Chapter 11 presents information on the needs of different stakeholders (manufacturers, regulators, payers, providers and patients) involved in this domain. The chapter qualitatively assesses the real world evidence related needs of each stakeholder group and the relative importance of their expectations within this domain.

Chapter 12 provides a comprehensive list of notable real world evidence use cases of pharmaceutical / medical device companies in the recent past (since 2016). The chapter highlights how these companies leveraged real world evidence to support their regulatory decisions, advance disease understanding and clinical guidelines, and assist outcome-based reimbursement decisions. In addition, the chapter presents an insightful opportunity analysis, estimating the existing market size and potential growth opportunities of real world evidence across different applications (early stage research, clinical development, regulatory approval, pricing / reimbursement, and post-approval studies). Based on multiple parameters, such as number of pre- or post-approval studies conducted annually, investment associated with these studies, and the likely cost and time saving opportunities, we have provided an informed estimate on the likely evolution of the market over the period 2018-2030. In addition, the report provides detailed market segmentation on the basis of type of real world data sources (medical claims, clinical trials, clinical setting, pharmacy, patient-powered and other data sources), therapeutic area (cardiovascular disorders, infectious diseases, metabolic disorders, neurological / psychiatric disorders, oncological disorders, and other disorders), and the geographical distribution of the market (North America, Europe, Asia-Pacific, and Rest of the World).

Chapter 13 presents the insights generated from a detailed survey, wherein we invited multiple stakeholders involved in the real world evidence domain. The participants, who were primarily Directors / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their offerings and the associated commercial potential.

Chapter 14 is a collection of transcripts of interviews conducted with various key stakeholders during the course of this study. We have presented the details of our discussions with Jane Reed (Head of Life Science Strategy, Linguamatics), Jonathan Moshinsky (Head of Market Strategy, uMotif) and Anonymous (Vice President, Big Pharmaceutical Company).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1 PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2 EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Need for Real World Evidence
3.1.1. Growing Crisis of Chronic Disorders
3.1.2. High Investment Involved in Drug Development
3.1.2.1. Role of Randomized Clinical Trials
3.1.2.2. Limitations of Randomized Clinical Trials
3.1.3. Increasing Shift from Volume- to Value-based Care
3.2. An Overview of Real World Evidence
3.2.1. Sources of Real World Data
3.2.1.1. Medical Claims Data
3.2.1.2. Clinical Trial Data
3.2.1.3. Clinical Settings Data
3.2.1.4. Patient-Powered Data
3.2.1.5. Pharmacy Data
3.2.1.6. Other Real World Data Sources
3.2.2. Comparison of Randomized Clinical Trials and Real World Evidence
3.2.3. Advantages and Limitations of Real World Evidence
3.2.4. Potential Applications of Real World Evidence
3.2.5. Growth Drivers and Challenges
3.3. Role of Advanced Techniques in Real World Data Management
4. DATA GOVERNANCE AND REGULATORY FRAMEWORK FOR REAL WORLD EVIDENCE
4.1. Chapter Overview
4.2. Primary Elements of Data Governance for Real World Evidence
4.3. Importance of Regulatory Framework for Real World Evidence
4.4. Data Governance and Regulatory Framework in North America
4.4.1. The US Scenario
4.4.1.1. Data Governance
4.4.1.2. Regulatory Framework
4.4.1.3. Future Recommendations
4.4.2. The Canadian Scenario
4.4.2.1. Data Governance
4.4.2.2. Regulatory Framework
4.4.2.3. Future Recommendations
4.5. Data Governance and Regulatory Framework in Europe
4.5.1. The UK Scenario
4.5.1.1. Data Governance
4.5.1.2. Regulatory Framework
4.5.1.3. Future Recommendations
4.5.2. The German Scenario
4.5.2.1. Data Governance
4.5.2.2. Regulatory Framework
4.5.2.3. Future Recommendations
4.5.3. The French Scenario
4.5.3.1. Data Governance
4.5.3.2. Regulatory Framework
4.5.3.3. Future Recommendations
4.5.4. The Spanish Scenario
4.5.4.1. Data Governance
4.5.4.2. Regulatory Framework
4.5.4.3. Future Recommendations
4.5.5. The Italian Scenario
4.5.5.1. Data Governance
4.5.5.2. Regulatory Framework
4.5.5.3. Future Recommendations
4.6. Data Governance and Regulatory Framework in Asia-Pacific
4.6.1. The Australian Scenario
4.6.1.1. Data Governance
4.6.1.2. Regulatory Framework
4.6.1.3. Future Recommendations
4.6.2. The Chinese Scenario
4.6.2.1. Data Governance
4.6.2.2. Regulatory Framework
4.6.2.3. Future Recommendations
4.6.3. The Japanese Scenario
4.6.3.1. Data Governance
4.6.3.2. Regulatory Framework
4.6.3.3. Future Recommendations

5. CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. List of Real World Evidence Solution Providers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Geographical Location
5.2.3. Analysis by Company Size
5.2.4. Analysis by Type of Offering
5.2.5. Analysis by Real World Data Sources
5.2.6. Analysis by Applications of Real World Evidence

6. PUBLICATION ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Real World Evidence: Publication Analysis
6.3.1. Analysis by Publication Year
6.3.2. Analysis by Key Focus Areas
6.3.3. Analysis by Real World Data Sources
6.3.4. Analysis by Key Indications Examined
6.3.5. Leading Players in Terms of Number of Published Studies
6.3.6. Analysis by Geographical Location of Leading Players
6.3.7. Key Journals

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Real World Evidence: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Geography and Number of Clinical Trials
7.3.3. Analysis by Geography and Enrolled Patient Population
7.3.4. Analysis by Trial Recruitment Status
7.3.5. Analysis by Type of Study
7.3.6. Analysis by Type of Sponsors / Collaborators
7.3.7. Most Active Players in Terms of Number of Trials
7.3.8. Analysis by Focus Areas
7.3.9. Analysis by Target Therapeutic Areas
7.3.10. Grid Analysis of Key Therapeutic Areas, 2013-2018
7.3.11. Benchmark Analysis of Key Industry Players

8. EMERGING TRENDS ON SOCIAL MEDIA
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Real World Evidence: Trends on Twitter
8.3.1. Historical Trends in Volume of Tweets
8.3.2. Popular Keywords
8.3.3. Popular Sources of Real World Data
8.3.4. Popular Applications of Real World Evidence
8.3.5. Popular Therapeutic Areas
8.3.6. Popular Stakeholders
8.3.7. Most Prolific Contributors
8.3.8. Most Influential Contributors

9. GLOBAL EVENTS ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Real World Evidence: Global Events Analysis
9.3.1. Analysis by Year of Occurrence
9.3.2. Analysis by Geography
9.3.3. Analysis by Type of Event
9.3.4. Analysis by Key Focus Area / Event Agenda
9.3.5. Most Active Event Organizers
9.3.6. Most Active Players in Terms of Event Participation
9.3.7. Analysis by Seniority Level of Participants
9.3.8. Geographical Mapping of Upcoming Events

10. SWOT ANALYSIS
10.1. Chapter Overview
10.2. Comparison of SWOT Factors

11. STAKEHOLDER NEEDS ANALYSIS
11.1. Chapter Overview
11.2. Real World Evidence: Needs of Stakeholders
11.2.1. Comparison of Needs of Stakeholders

12. REAL WORLD EVIDENCE USE CASES AND OPPORTUNITY ASSESSMENT
12.1. Chapter Overview
12.2. Real World Evidence Use Cases
12.3. Real World Evidence Market Opportunity Assessment
12.3.1 Methodology and Key Assumptions
12.3.2. Global Real World Evidence Market Opportunity, 2018-2030
12.3.3. Global Real World Evidence Market Opportunity by Type of Datasets
12.3.3.1.Real World Evidence Market Opportunity from Medical Claims Data, 2018-2030
12.3.3.2. Real World Evidence Market Opportunity from Clinical Trials Data, 2018-2030
12.3.3.3. Real World Evidence Market Opportunity from Clinical Settings Data, 2018-2030
12.3.3.4. Real World Evidence Market Opportunity from Patient-Powered Data, 2018-2030
12.3.3.5. Real World Evidence Market Opportunity from Pharmacy Data, 2018-2030
12.3.3.6. Real World Evidence Market Opportunity from Other Types of Data, 2018-2030
12.3.4. Global Real World Evidence Market Opportunity by Therapeutic Areas
12.3.4.1.Real World Evidence Market Opportunity in Cardiovascular Disorders, 2018-2030
12.3.4.2.Real World Evidence Market Opportunity in Infectious Diseases, 2018-2030
12.3.4.3.Real World Evidence Market Opportunity in Metabolic Disorders, 2018-2030
12.3.4.4.Real World Evidence Market Opportunity in Neurological / Psychiatric Disorders, 2018-2030
12.3.4.5.Real World Evidence Market Opportunity in Oncological Disorders, 2018-2030
12.3.4.6.Real World Evidence Market Opportunity in Other Types of Disorders, 2018-2030
12.3.5. Global Real World Evidence Market Opportunity by Applications
12.3.5.1.Real World Evidence Market Opportunity in Early Stage Research, 2018-2030
12.3.5.2.Real World Evidence Market Opportunity in Clinical Development, 2018-2030
12.3.5.3.Real World Evidence Market Opportunity in Regulatory Approval, 2018-2030
12.3.5.4.Real World Evidence Market Opportunity in Pricing / Reimbursement, 2018-2030
12.3.5.5.Real World Evidence Market Opportunity in Post-Approval Studies, 2018-2030
12.3.6. Regional Market Opportunities for Real World Evidence
12.3.6.1.Real World Evidence Market Opportunity in North America, 2018-2030
12.3.6.2.Real World Evidence Market Opportunity in Europe, 2018-2030
12.3.6.3.Real World Evidence Market Opportunity in Asia-Pacific, 2018-2030
12.3.6.4.Real World Evidence Market Opportunity in Rest of the World, 2018-2030

13. SURVEY INSIGHTS
13.1. Chapter Overview
13.2. Seniority Level of Respondents
13.3. Type of Offering
13.4. Real World Data Sources
13.5. Applications of Real World Evidence
13.6. Key Challenges in Generating Real World Evidence
13.7. Extent of Outsourcing
13.8. Current Market Opportunity

14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. Jane Reed, Head of Life Science Strategy, Linguamatics
14.3. Jonathan Moshinsky, Head of Market Strategy, uMotif
14.4. Anonymous, Vice President, Big Pharmaceutical Company

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1. Common Types of Chronic Disorders
Figure 3.2. Drug Development Costs: Year-wise Trend, 2000-2017 (USD Million)
Figure 3.3. Limitations of Randomized Clinical Trials
Figure 3.4. Process of Generating Evidence from Real World Data
Figure 3.5. Real World Data Sources
Figure 3.6. Potential Applications of Real World Evidence
Figure 3.7. Growth Drivers and Potential Roadblocks
Figure 4.1. Primary Elements of Data Governance for Real World Evidence
Figure 4.2. Ideal Regulatory Framework for Real World Evidence 
Figure 5.1. Real World Evidence Solution Providers: Distribution by Year of Establishment
Figure 5.2. Real World Evidence Solution Providers: Distribution by Geography 
Figure 5.3. Real World Evidence Solution Providers: Distribution by Company Size 
Figure 5.4. Real World Evidence Solution Providers: Distribution by Type of Offering 
Figure 5.5. Real World Evidence Solution Providers: Distribution by Real World Data Sources 
Figure 5.6. Real World Evidence Solution Providers: Distribution by Applications 
Figure 6.1. Publications: Historical Trends (2016-H1 2018) 
Figure 6.2. Publications: Distribution by Key Focus Areas 
Figure 6.3. Publications: Word Cloud Analysis of Study Titles 
Figure 6.4. Publications: Distribution by Real World Data Sources 
Figure 6.5. Publications: Key Indications in Terms of Number of Published Studies 
Figure 6.6. Publications: Distribution by Type of Sponsors 
Figure 6.7. Publications: Most Active Industry Players in Terms of Number of Published Studies 
Figure 6.8. Publications: Geographical Distribution of Authors
Figure 6.9. Publications: Key Journals 
Figure 7.1. Clinical Trials: Distribution by Trial Status 
Figure 7.2. Clinical Trials: Distribution by Registration Year 
Figure 7.3. Clinical Trials: Geographical Distribution by Number of Trials 
Figure 7.4. Clinical Trials: Geographical Distribution by Enrolled Patient Population 
Figure 7.5. Clinical Trials: Distribution by Registration Year and Enrolled Patient Population
Figure 7.6. Clinical Trials: Dot Plot of Number of Trials and Enrolled Patient Population
Figure 7.7. Clinical Trials: Distribution by Registration Year and Trial Recruitment Status 
Figure 7.8. Clinical Trials: Geographical Distribution by Registration Year and Recruitment Status 
Figure 7.9. Clinical Trials: Distribution by Type of Study 
Figure 7.10. Clinical Trials: Distribution by Registration Year and Type of Study 
Figure 7.11. Clinical Trials: Distribution by Type of Sponsors / Collaborators 
Figure 7.12. Clinical Trials: Most Active Industry Players in Terms of Number of Trials Conducted 
Figure 7.13. Clinical Trials: Most Active Non-Industry Players in Terms of Number of Trials Conducted 
Figure 7.14. Clinical Trials: Focus Areas 
Figure 7.15. Clinical Trials: Distribution by Therapeutic Areas 
Figure 7.16. Clinical Trials: Leading Indications in Terms of Number of Trials Conducted 
Figure 7.17. Clinical Trials: Distribution by Registration Year and Key Therapeutic Areas 
Figure 7.18. Clinical Trials: Year-wise Trend of Trials Conducted by Leading Industry Players, 2013-2018 
Figure 7.19. Clinical Trials: Benchmarking of Leading Industry Players by Number of Trials across Key Therapeutic Areas 
Figure 8.1. Trends on Social Media: Historical Activities on Twitter, 2013-2018 
Figure 8.2. Trends on Social Media: Year-wise Analysis by Volume, 2013-2018 
Figure 8.3. Trends on Social Media: Popular Keywords 
Figure 8.4. Trends on Social Media: Popular Real World Data Sources 
Figure 8.5. Trends on Social Media: Popular Applications of Real World Evidence 
Figure 8.6. Trends on Social Media: Popular Therapeutic Areas 
Figure 8.7. Trends on Social Media: Popular Stakeholders 
Figure 8.8. Trends on Social Media: Most Prolific Contributors 
Figure 8.9. Trends on Social Media: Most Influential Contributors
Figure 9.1. Global Events: Cumulative Quarter-wise Trend, Q1 2017-Q2 2018
Figure 9.2. Global Events: Distribution by Location 
Figure 9.3. Global Events: Distribution by Type 
Figure 9.4. Global Events: Key Focus Areas 
Figure 9.5. Global Events: Historical Trend of Event Agendas, Q1 2017-Q2 2018 
Figure 9.6. Global Events: Most Active Event Organizers
Figure 9.7. Global Events: Most Active Industry Players in Terms of Event Participation 
Figure 9.8. Global Events: Most Active Non-Industry Players in Terms of Event Participation 
Figure 9.9. Global Events: Distribution by Designations of Event Participants
Figure 9.10. Global Events: Distribution by Affiliated Departments of Event Participants 
Figure 9.11. Global Events: Geographical Mapping of Upcoming Events
Figure 10.1. Real World Evidence: SWOT Analysis
Figure 10.2. Comparison of SWOT Factors
Figure 11.1. Real World Evidence: Stakeholder Needs Analysis
Figure 11.2. Comparison of Needs of Stakeholders
Figure 12.1. Global Real World Evidence Market Opportunity, 2018-2030 (USD Million)
Figure 12.2. Real World Evidence Market Opportunity from Medical Claims Data, 2018-2030 (USD Million)
Figure 12.3. Real World Evidence Market Opportunity from Clinical Trials Data, 2018-2030 (USD Million)
Figure 12.4. Real World Evidence Market Opportunity from Clinical Settings Data, 2018-2030 (USD Million)
Figure 12.5. Real World Evidence Market Opportunity from Patient-Powered Data, 2018-2030 (USD Million)
Figure 12.6. Real World Evidence Market Opportunity from Pharmacy Data, 2018-2030 (USD Million)
Figure 12.7. Real World Evidence Market Opportunity from Other Types of Data, 2018-2030 (USD Million)
Figure 12.8. Real World Evidence Market Opportunity in Cardiovascular Disorders, 2018-2030 (USD Million)
Figure 12.9. Real World Evidence Market Opportunity in Infectious Diseases, 2018-2030 (USD Million)
Figure 12.10. Real World Evidence Market Opportunity in Metabolic Disorders, 2018-2030 (USD Million)
Figure 12.11. Real World Evidence Market Opportunity in Neurological / Psychiatric Disorders, 2018-2030 (USD Million)
Figure 12.12. Real World Evidence Market Opportunity in Oncological Disorders, 2018-2030 (USD Million)
Figure 12.13. Real World Evidence Market Opportunity in Other Types of Disorders, 2018-2030 (USD Million)
Figure 12.14. Real World Evidence Market Opportunity in Early Stage Research, 2018-2030 (USD Million)
Figure 12.15. Real World Evidence Market Opportunity in Clinical Development, 2018-2030 (USD Million)
Figure 12.16. Real World Evidence Market Opportunity in Regulatory Approval, 2018-2030 (USD Million)
Figure 12.17. Real World Evidence Market Opportunity in Pricing / Reimbursement, 2018-2030 (USD Million)
Figure 12.18. Real World Evidence Market Opportunity in Post-Approval Studies, 2018-2030 (USD Million)
Figure 12.19. Real World Evidence Market Opportunity in North America, 2018-2030 (USD Million)
Figure 12.20. Real World Evidence Market Opportunity in Europe, 2018-2030 (USD Million)
Figure 12.21. Real World Evidence Market Opportunity in Asia-Pacific, 2018-2030 (USD Million)
Figure 12.22. Real World Evidence Market Opportunity in Rest of the World, 2018-2030 (USD Million)
Figure 13.1. Survey Insights: Distribution by Type of Organization
Figure 13.2. Survey Insights: Distribution by Location of Organization 
Figure 13.3. Survey Insights: Distribution by Seniority Level 
Figure 13.4. Survey Insights: Distribution by Type of Offering 
Figure 13.5. Survey Insights: Distribution by Real World Data Sources 
Figure 13.6. Survey Insights: Distribution by Purpose of Real World Evidence Generation 
Figure 13.7. Survey Insights: Distribution by Key Challenges 
Figure 13.8. Survey Insights: Distribution by Extent of Outsourcing 
Figure 13.9. Survey Insights: Distribution by Current Market Opportunity

List of Tables

Table 3.1. Primary Elements of Different Sources of Real World Data
Table 3.2. Real World Evidence Opportunities in Pharmaceutical and Medical Device Industries
Table 3.3. Comparison of Randomized Clinical Trials and Real World Evidence
Table 5.1. List of Real World Evidence Solution Providers
Table 5.2. Real World Evidence Solution Providers: Information on Real World Data Sources and Applications
Table 7.1. List of Leading Clinical Trials by Enrolled Patient Population
Table 7.2. Grid Analysis of Key Therapeutic Areas and Number of Trials, 2013-2018
Table 12.1. Real World Evidence Use Cases, 2016-H1 2018
Table 13.1. Survey Insights: Overview of the Participating Organizations
Table 13.2. Survey Response: Seniority Level of Respondents
Table 13.3. Survey Insights: Type of Offering
Table 13.4. Survey Insights: Sources of Real World Data
Table 13.5. Survey Insights: Purpose of Real World Evidence Generation
Table 13.6. Survey Insights: Key Challenges
Table 13.7. Survey Insights: Extent of Outsourcing
Table 13.8. Survey Insights: Current Market Opportunity
Table 15.1. Drug Development Costs: Year-wise Trend 2000-2017 (USD Million)
Table 15.2. Real World Evidence Solution Providers: Distribution by Year of Establishment
Table 15.3. Real World Evidence Solution Providers: Distribution by Geography
Table 15.4. Real World Evidence Solution Providers: Distribution by Size (Employee Count)
Table 15.5. Real World Evidence Solution Providers: Distribution by Type of Offering 
Table 15.6. Real World Evidence Solution Providers: Distribution by Sources of Real World Data 
Table 15.7. Real World Evidence Solution Providers: Distribution by Applications 
Table 15.8. Publications: Historical Trends (2016-H1 2018) 
Table 15.9. Publications: Distribution by Key Focus Areas 
Table 15.10. Publications: Distribution by Real World Data Sources 
Table 15.11. Publications: Key Indications in Terms of Number of Published Studies 
Table 15.12. Publications: Distribution by Type of Sponsors
Table 15.13. Publications: Most Active Industry Players in Terms of Number of Published Studies
Table 15.14. Publications: Geographical Distribution of Authors
Table 15.15. Publications: Key Journals
Table 15.16. Clinical Trials: Distribution by Trial Status
Table 15.17. Clinical Trials: Distribution by Registration Year
Table 15.18. Clinical Trials: Geographical Distribution by Number of Trials
Table 15.19. Clinical Trials: Geographical Distribution by Enrolled Patient Population
Table 15.20. Clinical Trials: Distribution by Registration Year and Enrolled Patient Population
Table 15.21. Clinical Trials: Distribution by Registration Year and Trial Recruitment Status
Table 15.22. Clinical Trials: Geographical Distribution by Registration Year and Recruitment

List of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 23andMe
  2. 8KMiles
  3. Abbott
  4. AbbVie
  5. Acceliant
  6. Accenture
  7. Accsight
  8. Adarna Health Data
  9. Adelphi Real World
  10. Advera Health Analytics
  11. Aetion
  12. Allscripts
  13. Amazon Web Services
  14. American College of Cardiology
  15. American Diabetes Association
  16. Amgen
  17. Ana Health
  18. Analytica Laser
  19. Anthem
  20. Apple
  21. Arcana Institute
  22. Astellas Pharma
  23. AstraZeneca
  24. Axonal-Biostatem
  25. Axtria
  26. Bayer
  27. BC Platforms
  28. Biogen
  29. Boehringer Ingelheim
  30. Boston Health Economics
  31. Boston Scientific
  32. Bristol-Myers Squibb
  33. Cambridge Healthtech Institute
  34. CardioVascular Research Foundation
  35. CareFacets
  36. Caros Connect
  37. CBI
  38. Cegedim Strategic Data
  39. Centers for Disease Control and Prevention
  40. Chinese Academy of Medical Sciences
  41. CitiusTech
  42. CK Aspire
  43. Clarivate Analytics
  44. Clinakos
  45. ClinaMetrics
  46. Clinerion
  47. Clinical Trial EndPoint
  48. Clinigen Group
  49. Cloudera
  50. CloudMoyo
  51. Cogentia Healthcare Consulting
  52. Cognizant
  53. Conference Series
  54. ConvergeHEALTH
  55. Cota Healthcare
  56. Crossix Solutions
  57. Custodix
  58. D Cube Analytics
  59. Daichii Sankyo
  60. Data2Life
  61. Databricks
  62. Decision Driver Analytics
  63. Decision Resources
  64. Defense Intelligence Agency
  65. DIGIPHARM
  66. Digital Health Labs
  67. Drug Intelligence
  68. Duke University
  69. Dycros
  70. Edwards Lifesciences
  71. Eli Lilly
  72. Elligo Health Research
  73. Ephicacy
  74. EPID Research
  75. ESiOR
  76. European Medicines Agency
  77. Eurotrials
  78. Evidence Based Solutions
  79. Evidera
  80. evoMetrics
  81. Ernst & Young
  82. eyeforpharma
  83. Flatiron Health
  84. Flex
  85. Fuzzy Logix
  86. Genentech
  87. Genospace
  88. GNS Healthcare
  89. Google
  90. GlaxoSmithKline
  91. Harvard Medical School
  92. Healint
  93. Health IQ
  94. Health Solutions
  95. Healthagen
  96. HealthCore
  97. Healthing Research
  98. HealThink
  99. HealthVerity
  100. Humana
  101. Huron Consulting
  102. IBM Watson Health
  103. ICON
  104. Ignite Data
  105. Indegene
  106. Infosys
  107. Ingress Health
  108. InnoWin
  109. Inovalon
  110. Insight Pharmaceuticals
  111. Institute for Quality and Efficiency in Health Care
  112. Insys Group
  113. Intel
  114. International Society for Pharmacoeconomics and Outcomes Research
  115. IntrinsiQ Specialty Solutions
  116. IQVIA
  117. iwantGreatCare
  118. Janssen Pharmaceutica
  119. Johaus Global
  120. Johnson & Johnson
  121. Kaiku Health
  122. Kantar Health
  123. Karolinska Institutet
  124. Keedio
  125. Keyrus Biopharma
  126. Knowledgent
  127. Koneksa Health
  128. Kx Systems
  129. Lifecode Solutions
  130. Linguamatics
  131. LINK Medical Research
  132. Lundbeck
  133. LynxCare
  134. M2Gen
  135. M2S
  136. MA Provider
  137. MakroCare
  138. Mapi Group
  139. MarkLogic
  140. MarksMan Healthcare Communications
  141. Massachusetts General Hospital
  142. MaxisIT
  143. Mayo Clinic
  144. McKesson
  145. MDC Partners
  146. MeaningCloud
  147. Medaffcon
  148. Med-eShare
  149. MedEngine
  150. Medical Wisdom Consulting Group
  151. Medidata Solutions
  152. Medlior Health Outcomes Research
  153. Medpace
  154. MedStreaming
  155. Medtronic
  156. Merck
  157. Mercy
  158. MyOwnMed
  159. mySugr
  160. Northern Alberta Clinical Trials and Research Centre
  161. National Academies of Sciences, Engineering and Medicine
  162. National Cancer Institute
  163. National Institutes of Health
  164. National Institute of Mental Health
  165. National Institute on Drug Abuse
  166. National Investigation Agency
  167. New England Research Institute
  168. New York Heart Association
  169. NJ YZ Clinical Trials and Consulting
  170. Novartis
  171. Novo Nordisk
  172. Numerus
  173. Observational and Pragmatic Research Institute
  174. Odysseus Data Services
  175. OKRA Technologies
  176. OM1
  177. Omega CRO
  178. Oncocare Health
  179. OncoStats
  180. Optra Systems
  181. Optum
  182. OptumInsight
  183. Oracle
  184. ORPHA Strategy Consulting
  185. OXON Epidemiology
  186. Palantir
  187. PAREXEL
  188. Patient-Centered Outcomes Research Institute
  189. PatientsLikeMe
  190. PatientSource
  191. Peking University
  192. Peripharm
  193. PerkinElmer
  194. Pfizer
  195. pH Associates
  196. Pharma Intelligence
  197. Pharmaceuticals and Medical Devices Agency
  198. Pharmerit International
  199. PHARMO Institute
  200. Pinscriptive
  201. Point-of-Care Partners
  202. PotentiaMED
  203. PRA Health Sciences
  204. Precision Digital Health
  205. Precision Health AI
  206. Premier
  207. Qlik
  208. Quantify Research
  209. Quantzig
  210. Raven Biosciences
  211. Real Consulting Data
  212. Real Life Sciences
  213. RealHealthData
  214. Revon Systems
  215. Roam
  216. Roche
  217. RxAnte
  218. S3 Connected Health
  219. Saama Technologies
  220. Sanofi
  221. SAS Institute
  222. Savana
  223. Sciensus
  224. Sciformix
  225. Self Care Catalysts
  226. Sentry Data Systems
  227. SHYFT Analytics
  228. Society of Thoracic Surgeons
  229. Sprim Advanced Life Sciences
  230. SQN Clinical
  231. St. Jude Medical
  232. Stanford University
  233. StatFinn
  234. Sutter Health
  235. SVMPharma
  236. Symphony Health Solutions
  237. Syneos Health
  238. Synergus
  239. Syntel
  240. Takeda Pharmaceutical
  241. Talking Medicines
  242. TCD Outcomes Research
  243. Techtrials International
  244. Tempus
  245. Terrapinn Holdings
  246. TFS
  247. TransMed Systems
  248. TriAxia Health
  249. TriNetX
  250. Truven Health Analytics
  251. T-Systems
  252. Turacoz Healthcare Solutions
  253. uMotif
  254. United BioSource
  255. University of Alabama
  256. University of California
  257. University of Louisville
  258. University of North Carolina
  259. University of Pennsylvania
  260. University of Pittsburgh
  261. University of Texas
  262. US Department of Defense
  263. VA Office of Research and Development
  264. Validic
  265. Vector Oncology
  266. Verana Health
  267. Vestrum Health
  268. Vitaccess
  269. Vital Statistics Consulting
  270. Washington University School of Medicine
  271. Wellframe
  272. West Monroe Partners
  273. Wipro
  274. World Congress
  275. Worldwide Clinical Trials
  276. Xcenda
  277. Yale University
  278. Zeblok
  279. ZEINCRO
  280. Zephyr Health
  281. ZS Associates

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 3,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com